 | By OncoBeta GmbH OncoBeta® GmbH has announced its first Sydney-based patients were treated with Rhenium-SCT® as part of the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of non-melanoma skin cancer [NMSC]).
|
| By OncoBeta GmbH OncoBeta® GmbH today announces the first Austrian patients have been treated in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT– for the treatment of non-melanoma skin cancer). Prof. Dr.
|
| By OncoBeta GmbH The International Registry is an observational, multicentre, non-interventional program for patients diagnosed with non-melanoma skin cancer (NMSC), to inform treatment outcomes and patterns of care at international hospitals.
|
 | By OncoBeta GmbH OncoBeta® GmbH, a medical device company specialized in innovative epidermal radioisotope therapies announced today that the company has received ethics approval from the National Health and Medical Research Council (NHMRC) in Australia to begin the...
|
 | By OncoBeta GmbH Today OncoBeta® GmbH, a medical device company specialising in innovative epidermal radioisotope therapies for non-melanoma skin cancers (NMSCs), has expanded its offering of non-invasive skin cancer therapy Rhenium-SCT® (Skin Cancer Therapy) in South...
|
 | By OncoBeta GmbH The multi-centre prospective study will evaluate the efficacy of the Rhenium-SCT® in non-melanoma skin cancer patients
|
 | By OncoBeta GmbH Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer is now available in Australia
|
